3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Thrombocytopenia
7
Leukemia, Myeloid, Acute
6
Leukemia
5
Myelodysplastic Syndromes
3
Leukemia, Myelomonocytic, Chronic
2
Jacobs syndrome
2
Recurrence
1
Purpura, Thrombocytopenic, Idiopathic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Erythroblastic, Acute
1
Leukemia, Eosinophilic, Acute
1
Leukemia, Basophilic, Acute
1
Congenital Abnormalities
1
Blast Crisis
1
Anemia, Refractory, with Excess of Blasts
1
Anemia
1
Interventions
temsirolimus
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pazopanib
1
olaparib
1
eltrombopag
1
cc-486
1
Surveys and Questionnaires
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Doxorubicin
1
Docetaxel
1
Diphenhydramine
1
Cytarabine
1
Cyclophosphamide
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pathologic Complete Response
×
eltrombopag
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts